- Email: [email protected]
Cardiology: a call for papers
Comment
hypertrophy. These trials will also closely examine the potential for harm. As emphasised in the editorial that accompanied Palmer and colleagues’ study, the nephrology community should mobilise even more resources to support trials with clinical outcomes.19 Early understanding of activation of the vitamin D receptor successfully led to therapies for bone and mineral changes. As the function of this receptor’s activation in other cell types is unravelled, we remain optimistic about novel clinical applications. Ravi Thadhani Renal Unit and Center for D-Receptor Activation Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA [email protected] I have received research support from Abbott Pharmaceutical Division and honoraria from that company and Genzyme Corporation. I am supported by DK 071674, DK 76116, and M01 RR00088, all from the National Institutes of Health, USA. 1 2 3
4
5
Gray R, Boyle I, DeLuca HF. Vitamin D metabolism: the role of kidney tissue. Science 1971; 172: 1232–34. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–81. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–83. Eknoyan G, Levin A, Levin NW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 suppl 3): S1–201.
6 7
8
9
10
11
12
13
14 15 16 17 18
19
Steddon SJ, Cunningham J. Calcimimetics and calcilytics—fooling the calcium receptor. Lancet 2005; 365: 2237–39. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446–56. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2008; 147: 840–53. Garg AX, Hackam D, Tonelli M. Systematic review and meta-analysis: when one study is just not enough. Clin J Am Soc Nephrol 2008; 3: 253–60. Moriniere P, Fournier A, Leflon A, et al. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 1985; 39: 309–15. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358–63. Przedlacki J, Manelius J, Huttunen K. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 1995; 69: 433–37. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790–95. Imura A, Tsuji Y, Murata M, et al. α-Klotho as a regulator of calcium homeostasis. Science 2007; 316: 1615–18. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004–13. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770–73. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810–15. Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med 2008; 147: 880–81.
Cardiology: a call for papers To submit a paper go to http://ees.elsevier.com/thelancet
544
The Lancet is again dedicating a special issue to cardiology to coincide with the European Society of Cardiology Congress to be held in Munich, Germany, Aug 30 to Sept 3, 2008. We are particularly interested in original research papers that describe the results of randomised trials, but welcome submission of any other original research studies that will have an important effect on clinical practice or understanding of heart diseases. If your work falls under an embargo policy, please tell us the date, time, and manner of presentation (poster
or oral). If your paper is accepted here, publication on our website can be scheduled to coincide with the presentation. The deadline for submissions is May 4, 2008, via our online submission system. Please state in your covering letter that the submission is in response to this call for papers. Stuart Spencer The Lancet, London NW1 7BY, UK
www.thelancet.com Vol 371 February 16, 2008
hypertrophy. These trials will also closely examine the potential for harm. As emphasised in the editorial that accompanied Palmer and colleagues’ study, the nephrology community should mobilise even more resources to support trials with clinical outcomes.19 Early understanding of activation of the vitamin D receptor successfully led to therapies for bone and mineral changes. As the function of this receptor’s activation in other cell types is unravelled, we remain optimistic about novel clinical applications. Ravi Thadhani Renal Unit and Center for D-Receptor Activation Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA [email protected] I have received research support from Abbott Pharmaceutical Division and honoraria from that company and Genzyme Corporation. I am supported by DK 071674, DK 76116, and M01 RR00088, all from the National Institutes of Health, USA. 1 2 3
4
5
Gray R, Boyle I, DeLuca HF. Vitamin D metabolism: the role of kidney tissue. Science 1971; 172: 1232–34. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–81. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–83. Eknoyan G, Levin A, Levin NW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 suppl 3): S1–201.
6 7
8
9
10
11
12
13
14 15 16 17 18
19
Steddon SJ, Cunningham J. Calcimimetics and calcilytics—fooling the calcium receptor. Lancet 2005; 365: 2237–39. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446–56. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2008; 147: 840–53. Garg AX, Hackam D, Tonelli M. Systematic review and meta-analysis: when one study is just not enough. Clin J Am Soc Nephrol 2008; 3: 253–60. Moriniere P, Fournier A, Leflon A, et al. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 1985; 39: 309–15. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358–63. Przedlacki J, Manelius J, Huttunen K. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 1995; 69: 433–37. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790–95. Imura A, Tsuji Y, Murata M, et al. α-Klotho as a regulator of calcium homeostasis. Science 2007; 316: 1615–18. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004–13. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770–73. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810–15. Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med 2008; 147: 880–81.
Cardiology: a call for papers To submit a paper go to http://ees.elsevier.com/thelancet
544
The Lancet is again dedicating a special issue to cardiology to coincide with the European Society of Cardiology Congress to be held in Munich, Germany, Aug 30 to Sept 3, 2008. We are particularly interested in original research papers that describe the results of randomised trials, but welcome submission of any other original research studies that will have an important effect on clinical practice or understanding of heart diseases. If your work falls under an embargo policy, please tell us the date, time, and manner of presentation (poster
or oral). If your paper is accepted here, publication on our website can be scheduled to coincide with the presentation. The deadline for submissions is May 4, 2008, via our online submission system. Please state in your covering letter that the submission is in response to this call for papers. Stuart Spencer The Lancet, London NW1 7BY, UK
www.thelancet.com Vol 371 February 16, 2008